RxDoctor Payments DataLook up a doctor →

Raymond Lance, MD

Urology · Spokane, WANPI 1710930607

Payments from drug & device makers

$1,174,601in general payments, 2019–2025

Across 1,009 payments — averaging $1164.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$398K
  • Janssen Research & Development, LLC$270K
  • Johnson & Johnson$158K
  • Sumitomo Pharma America, Inc.$79K
  • Merck$76K
  • Veru Inc.$66K
  • plus $128K from 44 others
$404in research payments, 2019–2025

Across 1 payment — averaging $403.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$404

What the payments were for

  • Consulting fees$17,9078%
  • Speaking & faculty fees$153,02373%
  • Travel & lodging$25,93212%
  • Food & beverage$13,3866%
  • Education$6070%
  • Gifts$2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,174,601 in reported general payments places this provider in the 95th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$1,790,280
Medicare patients
630
Services billed
9,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide120$1,671,029
ErleadaApalutamide58$842,306
OrgovyxRelugolix242$632,241
XtandiEnzalutamide25$335,353
Abiraterone Acetate39$40,214
GemtesaVibegron25$14,084
MyrbetriqMirabegron16$10,016
Silodosin105$7,041
Finasteride517$4,325
Tamsulosin Hcl374$3,568
Potassium Citrate ErPotassium Citrate38$3,420
Medroxyprogesterone Acetate22$1,731
Bicalutamide56$1,677
Tolterodine Tartrate ErTolterodine Tartrate23$859
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$398,009$1,671,029120 claims
Johnson & JohnsonErleada$157,763$842,30658 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$79,059$646,325267 claims
Astellas Pharma US IncXtandi, Myrbetriq$16,406$345,36941 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$2,004$40,21439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Washington.

Other urology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →